OtoSCOPE® Genetic Hearing Loss Testing
The BEST comprehensive test for genetic forms of hearing loss including non-syndromic hearing loss, non-syndromic mimics (such as Usher Syndrome, Deafness-Infertility Syndrome, Perrault Syndrome and Pendred syndrome, among others) and common forms of syndromic hearing loss. In the Molecular Otolaryngology & Renal Research Laboratories (MORL), we continue to refine our diagnostic menu to provide the best testing options for your patients with hearing loss.
What is in OtoSCOPE® v9?
- Non-syndromic hearing loss (including 16 new genes)
- Common syndromes with hearing loss (including Pendred, Waardenburg, Stickler syndromes)
- Less common syndromes (CHARGE, Perrault, Brown-Vialetto-Van Laere syndromes)
- Syndromes affecting hearing and vision (Usher syndrome, CEP78, TMEM126A)
- Full list of OtoSCOPEv9 genes and conditions
- 2021 Hearing Test Requisition form
Why OtoSCOPE® and the MORL? Simple – get the best.
- Detailed, case-by-case review
- Every patient’s clinical history, hearing loss phenotype, and family history are discussed with our multidisciplinary Hearing Group
- Expertise and experience
- OtoSCOPE® was the first clinically available genetic testing platform for hearing loss. Over 5,000 patient have been tested on OtoSCOPE®
- MORL scientists have over 100 combined years of experience studying hereditary hearing loss
- MORL is recognized world-wide for expertise in addressing complexities of variant interpretation for hearing loss and deafness
- MORL provides on-going support for healthcare providers, including a dedicated hearing loss genetic counselor
- Commitment to advancing understanding of hearing and deafness
- Exploration of variants of uncertain significance through our HEAR VUS Program provides familial testing free of charge for qualifying families
- Innovative research in basic science, bioinformatics, and translational studies advances our understanding of hearing and deafness and improves clinical care
- Multiple publications highlight our contributions to the field and are widely available to the scientific community and general public
Next generation sequencing with read depth analysis for CNV detection.
Turnaround time is approximately 6 weeks.
8 - 10 cc. whole blood in lavender (EDTA) top tubes OR 10 μg DNA, minimum concentration: 50 ng/μl (A260/A280 1.8-2) resuspended in 0.1mM EDTA (10mM Tris HC1, 0.1mM EDTA, pH 8, Teknova Cat#T0220).
Cost & CPT Codes
See the MORL Testing Menu